After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...
UCB has received FDA approval for its drug Bimzelx for the treatment of moderate-to-severe hidradenitis suppurativa, or HS.
UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free ...
Commemorating a night full of soulful music, incredible theatricals, mouthwatering food and inspirational dialogues, UCB ...
A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus ...
United Community Banks, Inc. (NASDAQ:UCB – Get Free Report)’s stock price reached a new 52-week high during trading on Friday . The stock traded as high as $33.62 and last traded at $33.49, with a ...
The novel IL-17A and IL-17F inhibitor has been approved for moderate to severe hidradenitis suppurativa, a chronic and ...
This approval is the fifth overall for bimekizumab (Bimzelyx; UCB Pharma) in the US, and they all have come in the last 13 ...
UCB announced the FDA has approved BIMZELX for the treatment of adults with moderate-to-severe hidradenitis suppurativa. The approval ...
The board of United Community Banks, Inc. ( NYSE:UCB ) has announced that it will pay a dividend of $0.24 per share ...
On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback